Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Adeoye Olukotun Sells 2,000 Shares

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Adeoye Olukotun sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the transaction, the director directly owned 31,600 shares in the company, valued at approximately $2,747,936. This represents a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR traded down $1.94 during trading on Thursday, reaching $87.47. The company’s stock had a trading volume of 896,837 shares, compared to its average volume of 2,359,317. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. The firm has a market capitalization of $12.32 billion, a price-to-earnings ratio of -38.88 and a beta of 1.27. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $19.82 and a 12 month high of $95.49. The firm has a 50 day moving average price of $82.33 and a 200 day moving average price of $72.64.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The business had revenue of $75.25 million for the quarter, compared to the consensus estimate of $44.17 million. During the same period in the prior year, the business posted ($1.26) earnings per share. The firm’s revenue for the quarter was up 171.0% compared to the same quarter last year. As a group, equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Carolina Wealth Advisors LLC lifted its stake in Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 154 shares during the last quarter. CWM LLC increased its stake in shares of Arrowhead Pharmaceuticals by 1.4% in the 4th quarter. CWM LLC now owns 12,347 shares of the biotechnology company’s stock valued at $820,000 after purchasing an additional 168 shares during the last quarter. First Horizon Corp increased its stake in shares of Arrowhead Pharmaceuticals by 36.2% in the 1st quarter. First Horizon Corp now owns 654 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 174 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Arrowhead Pharmaceuticals by 1.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 11,102 shares of the biotechnology company’s stock worth $737,000 after buying an additional 178 shares in the last quarter. Finally, Optiver Holding B.V. raised its holdings in shares of Arrowhead Pharmaceuticals by 83.8% during the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after buying an additional 186 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ARWR shares. Chardan Capital raised their price objective on Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Royal Bank Of Canada upped their target price on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. HC Wainwright increased their target price on Arrowhead Pharmaceuticals from $115.00 to $120.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. B. Riley Financial raised their price target on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Finally, Morgan Stanley boosted their price target on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $97.33.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.